EMMYON, INC.
Rochester, MN · Biotech · Private
Small molecule therapeutic (EMMY1-06) to treat cancer-induced skeletal muscle atrophy
emmyon.com →- Grants
- $6.2M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 19
- 4 granted · 15 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Discovery of Novel Pharmaceutical Agents for Skeletal Muscle Atrophy | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Novel Small Molecule Therapies for Skeletal Muscle Atrophy | $746,147 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Novel Small Molecule Therapies for Skeletal Muscle Atrophy | $746,147 | |
| Federal grant | Department of Health and Human Services · Phase II · Discovery of Novel Pharmaceutical Agents for Skeletal Muscle Atrophy | $745,404 | |
| Federal grant | Department of Health and Human Services · Phase II · Discovery of Novel Pharmaceutical Agents for Skeletal Muscle Atrophy | $745,404 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of novel therapeutics for cancer cachexia | $990,411 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of novel therapeutics for cancer cachexia | $997,245 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of novel therapeutics for obesity and type 2 diabetes | $1,021,719 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1845 | Javelin Oncology, Inc. | — | $1.5M |
| 1846 | ABILITY Network Inc. | — | $20M |
| 1847 | Biena, LLC | — | $11M |
| 1848 | EMMYON, INC. | — | — |
| 1849 | VITRISTOR LLC | — | — |
| 1850 | ASP Isotopes Inc. | — | $5.0M |
| 1851 | Kymera Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Ursolic Acid Diethanolamine Saltapplication
- Ursolic Acid Morpholine Saltgranted
- Ursolic Acid Morpholine And Diethanolamine Saltsgranted
- FUROSTAN-3-OL Derivatives As Skeletal Muscle Hypertrophic Agentsgranted
- Ursolic Acid Morpholine And Diethanolamine Saltsapplication
- FUROSTAN-3-OL Derivatives As Skeletal Muscle Hypertrophic Agentsgranted
- FUROSTAN-3-OL Derivatives For The Treatment Of Obesity And Diabetesapplication
- FUROSTAN-3-OL Derivatives For The Treatment Of Obesity And Diabetesapplication
- Ursolic Acid Morpholine And Diethanolamine Saltsapplication
- Ursolic Acid Morpholine And Diethanolamine Saltsapplication
- Ursolic Acid Morpholine And Diethanolamine Saltsapplication
- FUROSTAN-3-OL Derivatives As Skeletal Muscle Hypertrophic Agentsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.